What the FDA labels say about taking them together
Lopinavir/ritonavir and rosuvastatin
Lopinavir/ritonavir's FDA label of July 23, 2026 names rosuvastatin in its drug interactions section, and rosuvastatin's label names lopinavir/ritonavir too. The lopinavir/ritonavir label: “Contraindicated due to potential for myopathy including rhabdomyolysis. Use atorvastatin with caution and at the lowest necessary dose. Titrate rosuvastatin dose carefully and use the lowest necessary dose; …”
Check it at the source: the lopinavir/ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.); the rosuvastatin FDA label on DailyMed (effective September 4, 2026, ScieGen Pharmaceuticals, Inc.).
What does the lopinavir/ritonavir label say about rosuvastatin?
Lopinavir/ritonavir label, drug interactionsConcomitant Drug Class/Drug Name: Lipid-modifying agents HMG-CoA Reductase Inhibitors: lovastatin simvastatin atorvastatin rosuvastatin Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ lovastatin ↑ simvastatin ↑ atorvastatin ↑ rosuvastatin ↑ lomitapide; Clinical Comments: Contraindicated due to potential for myopathy including rhabdomyolysis [see Contraindications ()]. Use atorvastatin with caution and at the lowest necessary dose. Titrate rosuvastatin dose carefully and use the lowest necessary dose; do not exceed rosuvastatin 10 mg/day. Lomitapide is a sensitive substrate for CYP3A4 metabolism. …
Source: FDA drug label (Kaletra), AbbVie Inc., effective July 23, 2026 (SPL set 8290add3-4449-4e58-6c97-8fe1eec972e3), via openFDA; the full label on DailyMed
What does the rosuvastatin label say about lopinavir/ritonavir?
Rosuvastatin label, drug interactionsAdditional Anti-Viral Medications Prevention or Management: Simeprevir Dasabuvir/ombitasvir/paritaprevir/ritonavir Elbasvir/grazoprevir Sofosbuvir/velpatasvir Glecaprevir/pibrentasvir Atazanavir/ritonavir Lopinavir/ritonavir Initiate with rosuvastatin 5 mg once daily, and do not exceed a dosage of rosuvastatin 10 mg once daily.
Crestor label (AstraZeneca Pharmaceuticals LP, April 29, 2026), drug interactionsLopinavir/ritonavir Initiate with CRESTOR 5 mg once daily, and do not exceed a dosage of CRESTOR 10 mg once daily.
Source: FDA drug label (Crestor, NDA021366), AstraZeneca Pharmaceuticals LP, effective April 29, 2026 (SPL set 325a5d0e-9a72-4015-9fcd-1655fb504cee), via openFDA
Source: FDA drug label (Rosuvastatin), ScieGen Pharmaceuticals, Inc., effective September 4, 2026 (SPL set ee4933c5-0d97-494d-ac0f-2083e0100836), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Lopinavir/ritonavir | Rosuvastatin | |
|---|---|---|
| Labeled for | HIV | Heart attack and coronary artery disease, High cholesterol, High triglycerides, Stroke prevention |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $4.46 per tablet 200-50 mg tablet | $0.0692 per tablet 40 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once